"After a thorough evaluation of studies from the University of Southern Denmark and Novo Nordisks internal safety assessment, Novo Nordisk is of the opinion that the benefit-risk profile of semaglutide remains unchanged," the company noted
Sulphonylureas (e.g., gliclazide) and thiazolidinediones (e.g., pioglitazone) are older oral agents still used in certain situations, though they are less commonly prescribed due to side effect profiles, including weight gain and hypoglycaemia risk
Particulate matter in injectable solutions can cause injection-site reactions, embolism, or immune responses
Because DSIP has not been thoroughly studied in humans, people who are pregnant or breastfeeding, have significant medical conditions, or take multiple medications should avoid using it unless advised by a qualified healthcare professional
any concurrent use requires specialist supervision and careful monitoring